Ann M. Ginsberg, M.D., Ph.D., is Deputy Director, TB Vaccines in the Global Health Division of the Bill & Melinda Gates Foundation. She has conducted and managed TB research and product development programs for 25 years, including 15 years leading and designing clinical strategy for development of TB vaccines and drug regimens for the developing world. Ann previously served as the Chief, Respiratory Diseases Branch, NIAID, NIH, as Director, Project Management at Merck Research Laboratories, as Chief Medical Officer at the Global Alliance for TB Drug Development, as Chief Medical Officer at Aeras and as Senior Technical Advisor at IAVI. In these roles, she oversaw the early clinical development program of Pretomanid and two recent, positive TB vaccine efficacy trials – of BCG revaccination and M72/AS01E. Ann has served on numerous national and international advisory committees on vaccines and global health, including the U.S. National Vaccine Advisory Committee. Her AB cum laude in Biology is from Harvard University, her PhD in Molecular Biology from Washington University and her MD from Columbia University. She was Board-certified in Anatomic Pathology.
